Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | CAR-T updates in myeloma

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares some insights into recent updates in CAR-T therapy for the treatment of multiple myeloma. Prof. Raje first discusses how the approval of ciltacabtagene autoleucel (cilta-cel) has improved options for triple-class refractory and penta-refractory patients, and further explains the promise of idecabtagene vicleucel (ide-cel) and the importance of real-world data. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.